Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 275

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma

Open access
Tong, Chuan, Zhang, Yajing, Liu, Yang, Ji, Xingyu, Zhang, Wen-ying, Guo, Yelei, Han, Xiao, Ti, Dongdong, Dai, Hanren, Wang, Chunmeng, Yang, Qingming, Liu, Wanli, Wang, Yao, Wu, Zhiqiang, Han, Weidong · 2020 · Blood

Abstract

Chimeric antigen receptor T (CAR T) cells targeting CD19 have achieved breakthroughs in the treatment of hematological malignancies, such as relapsed/refractory non-Hodgkin lymphoma (r/rNHL); however, high rates of treatment failure and recurrence after CAR T cell therapy are considerable obstacles to overcome. In this study, we designed a series of tandem CARs (TanCARs) and found that TanCAR7 T cells not only showed dual antigen targeting of both CD19 and CD20 but also formed superior and stable immunological synapse (IS) structures, which may be related to their robust antitumor activity. In an open-label, single-arm phase I/IIa trial (ClinicalTrials.gov number NCT03097770), we enrolled 33 patients with r/rNHL, and a total of 28 patients received an infusion after conditioning chemotherapy. The primary objective was to evaluate the safety and tolerability of TanCAR7 T cells. Efficacy, progression-free survival and overall survival were evaluated as secondary objectives. Cytokine release syndrome (CRS) occurred in 14 patients (50%), with 36% grade 1 or 2 and 14% grade 3. No cases of CAR T cell-related encephalopathy syndrome (CRES) of grade 3 or higher were confirmed in any patient. One patient died from a treatment-associated severe pulmonary infection. The overall response rate was 79% (95% confidence interval [CI], 60 to 92), and the complete response rate was 71%. The progression-free survival rate at 12 months was 64% (95% CI, 43 to 79). In this study, TanCAR7 T cells elicited a potent and durable antitumor response but not grade 3 or higher CRES in patients with r/rNHL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2020005278

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 275

Metadata

Authors
Tong, C., Zhang, Y., Liu, Y., Ji, X., Zhang, W.-Y., Guo, Y., Han, X., Ti, D., Dai, H., Wang, C., Yang, Q., Liu, W., Wang, Y., Wu, Z., & Han, W.
Venue
Blood
Published
2020-06-18
Volume
136
Issue
14
Pages
1632-1644
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W3036279197
Cited by
275
References
43
FWCI
12.83
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma. https://app.cochat.ai/papers/10.1182/blood.2020005278
The paper
Tong, C., Zhang, Y., Liu, Y., Ji, X., Zhang, W.-Y., Guo, Y., Han, X., Ti, D., Dai, H., Wang, C., Yang, Q., Liu, W., Wang, Y., Wu, Z., & Han, W. (2020). Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma. Blood. https://doi.org/10.1182/blood.2020005278

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.